Table 1 Baseline characteristics and optimized background
DRV/rtv + ENF+ OBR (n = 21) | TPV/rtv + ENF + OBR (n = 12) | Other + ENF + OBR (n = 4) | All patients (N = 37) | |
|---|---|---|---|---|
Demographics | ||||
Male | 19 | 10 | 4 | 33 |
Mean age, years (±SD) | 43 (7.7) | 47 (11.2) | 45 (6.2) | 44.8 (8.79) |
Disease characteristics | ||||
Median duration of infection (range) | 13 (8–22) | 13 (5–19) | 14 (5–19) | 13 (5–22) |
Median baseline log 10 HIV RNA (range) | 4.22 (1.80-5.76) | 4.18 (3.45-5.59) | 4.20 (2.54-5.00) | 4.22 (1.80-5.76) |
Median CD4+ cells count, cell per mL (range) | 177 (20–508) | 301 (74–561) | 119 (8–339) | 224 (8–561) |
CDC class, n (%) | ||||
A | 3 (14.2%) | 1 (8.3%) | 0 | 4 (10.8%) |
B | 6 (28.5%) | 2 (9.5%) | 1 (25%) | 9 (24.3%) |
C | 12 (57.1%) | 9 (42.8%) | 3 (75%) | 24 (64.8%) |
History of antiretroviral treatment | ||||
Median of previous ARV treatments (range) | 5 (3–10) | 5.5 (4–12) | 5.5 (5–7) | 5 (3–12) |
Baseline resistance | ||||
Primary IAS-USA [[10]] PI mutations (range) | 2 (0–5) | 2 (0–6) | 3 (0–5) | 2 (0–6) |
PI RAMs | 3 (1–7) | 4.5 (2–7) | 4 (1–7) | 4 (1–7) |
NRTI RAMs | 5 (0–8) | 6 (4–7) | 4 (2–4) | 5 (0–8) |
NNRTI RAMs | 1 (0–3) | 1 (0–4) | 2 (0–2) | 1 (0–4) |
Number of active ARV in OBR, n (%) | ||||
0 | 0 | 1 (8.3%) | 0 | 1 (2.7%) |
1 | 4 (19%) | 8 (66.6%) | 1 (25%) | 13 (35.1%) |
≥2 | 17 (81%) | 3 (25%) | 3 (75%) | 23 (62.2%) |
*GSS OBR, Median (IQR) | 2.0 (1.50-2.25) | 1.13 (1.0-1,38) | 2.0 (1.63-2.13) | 1.50 (1.25-2.00) |
GSS OBR, n (%) | ||||
≥2 | 12 (57.1%) | 0 (0%) | 3 (75%) | 15 (40.5%) |
1 to <2 | 9 (42.8%) | 11 (91.6%) | 1 (25%) | 21 (56.8%) |
0 to <1 | 0 (0%) | 1 (8.33%) | 0 | 1 (2.7%) |
Three most used ARV in OBR, n (%) | ||||
TDF | 7 (33.3%) | 7 (58%) | 3 (75%) | 17 (46%) |
RAL | 19 (90%) | 9 (75%) | 4 (100%) | 32 (86%) |
ETV | 4 (19%) | 0 | 1 (25%) | 5 (13.5%) |